- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04885088
Smart Home Care of Cloud Base ECG on the Cardiotoxicity Prevention on the Cancer Patients. (AI)
Thoracic malignancy is the most commonly diagnosed cancer worldwide.1,2 The incidence of thoracic malignancy has decreased in North America, but not in Asia, where it continues to show an increasing trend. A notable manifestation of the bimodal age distribution of thoracic malignancy has been observed in women. The occurrence of early-onset thoracic malignancy in the Asian population is earlier than that in the Western population, resulting in a higher incidence of thoracic malignancy in young Asian women. Moreover, the late onset age distribution of patients with thoracic malignancy in Asia (40-50 years) is earlier than that in Western countries (60-70 years), peaking at the age of 45-50 years in most women. The age-specific incidence rates of thoracic malignancy increase sharply until the menopausal stage.
Cardiovascular morbidity is higher among women with thoracic malignancy involving the thorax who had received radiotherapy (RT) compared with those not involving the thorax but receiving the same treatment. Thus far, the risks and time to onset of cardiac complications have been unclear in both young and old women. The proportion of young women with thoracic malignancy is higher in Asia than in Western countries. Furthermore, whether Asian women with thoracic malignancy are susceptible to RT remains unclear.
Anthracyclines are important therapeutic agents for breast cancer. Anthracycline-based regimens have similar or improved outcomes relative to the standard treatment regimen of cyclophosphamide, methotrexate, and fluorouracil. However, cardiotoxicity is a long-term toxicity associated with these regimens. The combined use of adjuvant anthracycline-based chemotherapy (CT) and RT may result in high cardiotoxicity. Nonetheless, no clear information on the effects of this combined therapy on the time to onset of both cardiac complications and cardiotoxicity is available. Furthermore, whether the cardiotoxicity of adjuvant RT and anthracycline-based CT is associated with age and ethnicity in women with thoracic malignancy remains unclear.
Therefore, cardiovascular disease is undoubtedly one of the most challenging health problems in the world. More efforts are needed to prevent and better control of this disease. Our proposed monitoring program is to use AI to monitor the basal value variation of personalized cardiovascular disease in cancer patients before and after chemoradiation. In the first year, our team focused on cardiotoxicity associated with cardiovascular disease models and cancer treatments. In the second year, we will apply knowledge in a clinical setting and calculate the severity of cardiac toxicity and its incidence and time response after cancer treatment. In the third year, high-risk groups will be identified to provide preventive intervention to reduce the risk of cancer-treatment related cardiotoxicity.
연구 개요
상세 설명
This study is open, prospective study, multi-center, randomized controlled trial, unobtrusive research. This study is start on June 1 2021. And will include 400 patients who have just cardiotoxicity of adjuvant RT and anthracycline-based CT patients who diagnosis of Thoracic malignancy. And random allocation 200 experimental group (Non-invasive Wearable Device) and 200 control group (routine medical).
Ask whether the patients who meet the exclusion criteria are willing to participate in the screening (Screening), if they are willing to join and sign the consent of the subject, and after the patient's condition is stable, conduct an electrocardiogram (V0) before discharge from the hospital. On day 7 (±2 weeks), day 84 (±4 weeks), 168 days (±4 weeks), 252 days (±4 weeks), 336 days (±8 weeks) during routine clinical referral (V1-V5) Both are done once. The results of these two tests and other basic information of the patient, including Demography, Vital Signs, High, Weight, Medication, and European and Taiwan Cardiology Association recommended routine test results of high-risk patients, including Blood Chemistry Panel, NT-proBNP, Echocardiography, Myocardial Perfusion Scan, etc., will record the information of the logged-in subjects on the paper case report form. The CRF only displays the study number, and no subject is available. In addition to the examination of each return visit, the subjects also took the ECG bracelet home at the time of discharge (V0) and wore it every day. After the discharge, the ECG was measured every morning and evening, and their personal activity and sleep were collected. Relevant information. After the subject was discharged from the hospital, the subject tracked the date of all adverse events due to cardiovascular disease within one year, including: heart failure, restenosis due to blood vessel, and non-fatal myocardial infarction , To do blood vessel-related surgery again, and data on the occurrence of death.
연구 유형
등록 (예상)
연락처 및 위치
연구 연락처
- 이름: YU ANN FANG, MS
- 전화번호: 8891 886-2-22490088
- 이메일: runawayyu@hotmail.com
연구 연락처 백업
- 이름: Ju-Chi Liu, PHD, MD
- 전화번호: 8170 886-2-22490088
- 이메일: liumdcv@tmu.edu.tw
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- ≥ 20-year-old
- Patients who had received radiotherapy (RT) or anthracycline-based CT or cancer immunotherapy or Targeted Therapy
- Diagnosis of Thoracic malignancy or breast cancer.
- Willing to sign the consent form of the subject and cooperate with the return visit
- Those who are admitted to the hospital and enter the general ward can receive the first ECG heart sound examination
Exclusion Criteria:
- <20-year-old
- Can't received radiotherapy (RT) or anthracycline-based CT or cancer immunotherapy or Targeted Therapy
- Those who cannot perform the first examination after being admitted to the hospital and entering the general ward
- It is impossible to measure the group of ECG and heart sounds. For example, when using Pacemaker, the ECG showed ventricular tachycardia (VT) and Dextrocardia on admission.
- Patients who are bedridden and have difficulty in cooperating with return visits
- Any subject that the physician believes is at high risk for future uncooperative tracking
- Direct participants in this program
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
Interventions
Device: Wisdom bracelet Other Names: control group (routine medical) |
Wisdom bracelet
|
control
routine medical Non-invasive Wearable Device
|
Wisdom bracelet
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
죽음
기간: 1년 이내
|
죽음, 예 또는 아니오로 나뉩니다.
|
1년 이내
|
심부전
기간: 1년 이내
|
퇴원 후 심부전으로 병원 재 방문(의사 판단), 예, 아니오로 나누어
|
1년 이내
|
Acute Coronary Syndrome, Coronary Artery Disease
기간: Within a year
|
Come back to the hospital for Acute Coronary Syndrome, Coronary Artery Disease (Judged by the physician) after discharge, divided into yes or no
|
Within a year
|
Myocarditis
기간: Within a year
|
Come back to the hospital for Myocarditis (Judged by the physician) after discharge, divided into yes or no
|
Within a year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
의사가 약을 조정합니다.
기간: 1년 이내
|
의사가 내린 약 지시에 따라 약의 조정이 있으면 기록하고예 또는 아니오로 나눕니다.
|
1년 이내
|
의사가 조기에 검사를 준비합니다.
기간: 1년 이내
|
의사가 심장초음파 또는 SPECT를 이용한 스트레스 및 재분배 심근 관류 스캔을 하기로 한 경우 비 테이블 기간 동안 예 또는 아니오로 구분
|
1년 이내
|
규정 준수
기간: 1년 이내
|
의사가 판단하여 환자가 상담에 복귀하면 환자는 과거에 약물 순응도에 대해 묻고 예 또는 아니오로 나뉩니다.
|
1년 이내
|
의료비
기간: 1년 이내
|
지난 1년 동안 환자의 모든 의료 및 건강 보험 비용의 합계
|
1년 이내
|
Arrhythmia
기간: Within a year
|
Re-hospitalization for Arrhythmia (Judged by the physician) after discharge, divided into yes or no
|
Within a year
|
Valvular Heart Disease
기간: Within a year
|
Re-hospitalization for Valvular Heart Disease (Judged by the physician) after discharge, divided into yes or no
|
Within a year
|
공동 작업자 및 조사자
스폰서
협력자
수사관
- 연구 의자: Ju-Chi Liu, PHD, MD, Taipei Medical University Shuang Ho Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .